Serious infections with antirheumatic therapy: Are biologicals worse?

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their-risk.

Original languageEnglish (US)
JournalAnnals of the Rheumatic Diseases
Volume65
Issue numberSUPPL. 3
DOIs
StatePublished - Nov 2006

Fingerprint

Biological Therapy
Rheumatoid Arthritis
Methotrexate
Infection
Biological Factors
Prednisone
Adrenal Cortex Hormones
Screening
Vaccines
Physicians
Therapeutics
Research

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Serious infections with antirheumatic therapy : Are biologicals worse? / Winthrop, Kevin.

In: Annals of the Rheumatic Diseases, Vol. 65, No. SUPPL. 3, 11.2006.

Research output: Contribution to journalArticle

@article{863b1bb540cc4deb9d586be5cae57bc3,
title = "Serious infections with antirheumatic therapy: Are biologicals worse?",
abstract = "This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their-risk.",
author = "Kevin Winthrop",
year = "2006",
month = "11",
doi = "10.1136/ard.2006.058503",
language = "English (US)",
volume = "65",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Serious infections with antirheumatic therapy

T2 - Are biologicals worse?

AU - Winthrop, Kevin

PY - 2006/11

Y1 - 2006/11

N2 - This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their-risk.

AB - This paper reviews the current evidence for the role of antirheumatic therapy in the development of serious infections in patients with rheumatoid arthritis (RA). Prednisone is clearly associated with increased infectious risk, but no definitive data link methotrexate to infection. Emerging data suggest that biological agents also pose increase infectious risk, particularly when used in combination with corticosteroids or methotrexate. Further research is needed in this important aspect of RA treatment. In the meantime, the author recommends that physicians should remain vigilant for serious infections in their patients with RA and use appropriate vaccines and screening procedures to mitigate their-risk.

UR - http://www.scopus.com/inward/record.url?scp=33750293973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750293973&partnerID=8YFLogxK

U2 - 10.1136/ard.2006.058503

DO - 10.1136/ard.2006.058503

M3 - Article

C2 - 17038474

AN - SCOPUS:33750293973

VL - 65

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - SUPPL. 3

ER -